CT在线自适应放疗与前列腺癌剂量学及急性毒性改善相关
单中心分析158例接受60 Gy/20次的前列腺癌患者,比较CT在线自适应放疗(COA,n=81)与非自适应放疗(n=77)。COA显著降低胃肠道毒性(OR 0.45,95%CI 0.27-0.73,p=0.001),未显著降低泌尿生殖毒性(OR 0.65,95%CI 0.40-1.03,p=0.07),且精囊受照长度与剂量学获益正相关(r=0.42,p<0.001)。
要点
- COA与短期胃肠道毒性降低显著相关,OR 0.45(95%CI 0.27-0.73,p=0.001)。
- COA对泌尿生殖毒性无显著影响,OR 0.65(95%CI 0.40-1.03,p=0.07)。
- 精囊受照长度与COA剂量学获益正相关(r=0.42,p<0.001)。
核心结论
- COA与剂量学改善和短期胃肠道毒性降低相关,精囊每日位置变化是COA改善结局的主要机制。
研究设计与样本
- 单中心回顾性分析158例接受60 Gy/20次的前列腺癌患者,COA组81例每日计划自适应,非自适应组77例。
主要发现
- 多因素分析中COA显著降低胃肠道毒性(OR 0.45,95%CI 0.27-0.73,p=0.001),未显著降低泌尿生殖毒性(OR 0.65,95%CI 0.40-1.03,p=0.07)。
- 1620次COA分次中48.4%出现临床获益的剂量学变化,靶区覆盖、直肠、小肠和膀胱分别占63.7%、20.0%、15.1%和2.3%。
- 79/81(97.5%)COA患者至少一次分次超过预设临床获益阈值。
- 精囊受照长度与COA剂量学获益正相关(r=0.42,p<0.001)。
- 非自适应患者中精囊受照长度与短期胃肠道毒性相关(r=0.30,p=0.009),COA后该关联消失。
关键数值与推荐
- COA组胃肠道毒性OR 0.45(95%CI 0.27-0.73,p=0.001),泌尿生殖毒性OR 0.65(95%CI 0.40-1.03,p=0.07)。
- COA分次中48.4%有临床获益剂量学变化,靶区覆盖63.7%、直肠20.0%、小肠15.1%、膀胱2.3%。
- 精囊受照长度与剂量学获益相关系数r=0.42(p<0.001),与非自适应组胃肠道毒性相关系数r=0.30(p=0.009)。
临床怎么用
- 前列腺癌放疗可考虑COA以降低短期胃肠道毒性,尤其需关注精囊受照长度较大的患者。
局限性
- 单中心回顾性设计,样本量158例,短期毒性评估,需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: CT online adaptive (COA) radiotherapy allows for daily personalization of radiotherapy plans based on cone-beam CT imaging. Presently, the impact of COA on prostate cancer outcomes remains unknown. MATERIALS AND METHODS: Records of 158 prostate cancer patients treated to 60 Gy/20 fractions in a single department with either COA with daily plan adaptation (n = 81) or non-adaptive radiotherapy (n = 77) were analyzed. Dosimetric changes resulting from COA were assessed. Short-term gastrointestinal (GI) and genitourinary (GU) toxicities were graded and logistic regression analyses with inverse probability treatment weighting (IPTW) were performed to assess the effect of COA on toxicities. The length of seminal vesicle tissue treated (LSV) was assessed as a predictor of COA outcomes. RESULTS: On multivariate analysis, COA was significantly associated with reduced GI toxicity (OR 0.45 95 %CI 0.27-0.73, p = 0.001) but not GU toxicity (OR 0.65 95 %CI 0.40-1.03, p = 0.07). Of 1620 COA fractions, 48.4 % demonstrated a clinically beneficial dosimetric change (63.7 %, 20.0 %, 15.1 % and 2.3 % for target coverage, rectum, small bowel and bladder, respectively) and 79/81 (97.5 %) of COA patients experienced at least one fraction exceeding a pre-defined threshold for clinical benefit. LSV was positively correlated with dosimetric benefit from COA (r = 0.42, p < 0.001). In non-adaptive patients, the LSV was associated with short-term GI toxicity (r = 0.30, p = 0.009) whereas this association was abolished with COA. CONCLUSIONS: COA is associated with dosimetric improvements and decreased short-term GI toxicity. Accounting for daily variation in seminal vesicle position is a primary mechanism by which COA improves outcomes.
引用
- Zhu LL, Bredfeldt JS, Hu YH, et al. CT online adaptive radiotherapy is associated with dosimetric and acute toxicity improvements in prostate cancer treatment. Radiother Oncol. 2025. PMID: 41110806. doi:10.1016/j.radonc.2025.111207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。